Other Events ·
Tiziana Life Sciences announced on July 31, 2026, that the third patient with Multiple System Atrophy (MSA) in its…
TLSATiziana Life Sciences Ltd
Tiziana Life Sciences announced on July 31, 2026, that the third patient with Multiple System Atrophy (MSA) in its Phase 2 clinical trial has completed dosing with intranasal foralumab. Quantitative PET imaging results showed up to a 34% reduction in standardized uptake value and a 26% reduction in standardized uptake value ratio in brain regions affected by MSA, consistent with findings from the first two patients. These data reinforce evidence of biological activity in dampening neuroinflammation. Tiziana Life Sciences Ltd is a clinical-stage biopharmaceutical company developing therapies using transformational drug delivery technologies for immunotherapy.